Enanta Pharmaceuticals
ENTA
170 hedge funds and large institutions have $1.4B invested in Enanta Pharmaceuticals in 2022 Q1 according to their latest regulatory filings, with 19 funds opening new positions, 64 increasing their positions, 66 reducing their positions, and 30 closing their positions.
155% more call options, than puts
Call options by funds: $4.49M | Put options by funds: $1.76M
3.36% more ownership
Funds ownership: 92.46% → 95.82% (+3.4%)
0% more funds holding in top 10
Funds holding in top 10: 4 → 4 (0)
0% less capital invested
Capital invested by funds: $1.4B → $1.4B (-$5.02M)
3% less repeat investments, than reductions
Existing positions increased: 64 | Existing positions reduced: 66
6% less funds holding
Funds holding: 181 → 170 (-11)
37% less first-time investments, than exits
New positions opened: 19 | Existing positions closed: 30
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCM
RA Capital Management
Boston,
Massachusetts
|
+$62.7M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
+$15.8M |
| 3 |
DTC
Deep Track Capital
Greenwich,
Connecticut
|
+$12.9M |
| 4 |
State Street
Boston,
Massachusetts
|
+$11.8M |
| 5 |
SCM
Stonepine Capital Management
Bend,
Oregon
|
+$7.81M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DGM
Darwin Global Management
St. Helier,
Jersey
|
-$12.4M |
| 2 |
First Manhattan
New York
|
-$11.7M |
| 3 |
GIM
Granahan Investment Management
Waltham,
Massachusetts
|
-$9.24M |
| 4 |
SCM
Soleus Capital Management
Greenwich,
Connecticut
|
-$7.53M |
| 5 |
Renaissance Technologies
New York
|
-$6.98M |
ENTA Hedge Fund Activity: Q1 2022 in Review
170 of the 6,360 institutional investors tracked by Wall St. Rank reported a position in Enanta Pharmaceuticals (ENTA) for Q1 2022, worth a combined $1.4B — down 0.36% from $1.4B a quarter earlier.
Sellers outnumbered buyers: 30 funds closed out of ENTA and 19 opened new positions — a net loss of 11 holders — while 66 trimmed existing stakes and 64 added.
The largest buyer was RA Capital Management, opening a new position worth an estimated $62.7M. The largest seller was Darwin Global Management, exiting entirely with an estimated $12.4M sold.
- 170 institutional investors held Enanta Pharmaceuticals (ENTA) as of Q1 2022, down from 181 in Q4 2021.
- Funds reported $1.4B of Enanta Pharmaceuticals stock for Q1 2022, down 0.36% quarter-over-quarter.
- 19 funds opened new Enanta Pharmaceuticals positions in Q1 2022 and 30 closed out, a net change of -11 holders.
- The largest Enanta Pharmaceuticals buyer in Q1 2022 was RA Capital Management, an estimated $62.7M added.
- The largest Enanta Pharmaceuticals seller in Q1 2022 was Darwin Global Management, an estimated $12.4M sold.
Based on aggregated 13F filings for Q1 2022.